2 suspended. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Suspended 2 |
| Phase 2 | 1 | Suspended 1 |
Follow Intensity-Modulated Radiotherapy: new trials by email Literature Review of Intensity-Modulated Radiotherapy trials Research Report on Intensity-Modulated Radiotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer Biospecimen Collection, Cemiplimab, Computed Tomography - Eyelid Squamous Cell Carcinoma, Recurrent Eyelid Squamous Cell Carcinoma | Phase 3 | Suspended | National Cancer Institute (NCI) | 420 | 2025-02-18 | 2026-11-03 |
| Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer Atezolizumab, Biopsy Procedure, Biospecimen Collection - Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7 | Phase 2 / Phase 3 | Suspended | National Cancer Institute (NCI) | 613 | 2013-03-22 | 2026-11-02 |
Squamous Cell Carcinoma of Head and Neck (1)
National Cancer Institute (NCI) (2)
Canada (2) · United States (2) · Australia (1) · Hong Kong (1)
Neil D Gross (1) · Paul M Harari (1)
U10CA180868 (2), U10CA021661 (1)